THERAPY DOSSIER · th-5c681c7c6253

LP17 TREM-1 inhibitory peptide in nanomicelles; antagomir-155 used as a mechanistic tool

Drug

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Endotoxin/LPS
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 5

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT03158948 ↗PHASE2completed

CLASS-LEVEL SURROGATE (nangibotide/LR12, a different TREM-1 inhibitory peptide): Phase 2 Safety, PK and PD of MOTREM in Septic Shock

Shock, Septic

Enrolment: 50 · Results not recorded

NCT04055909 ↗PHASE2active not recruiting

CLASS-LEVEL SURROGATE (nangibotide): Efficacy, Safety and Tolerability of Nangibotide in Septic Shock

Shock, Septic

Enrolment: 355 · Results not recorded

NCT04429334 ↗PHASE2completed

CLASS-LEVEL SURROGATE (nangibotide): ESSENTIAL Study of Nangibotide in COVID-19 Patients With Ventilatory Support

COVID19

Enrolment: 220 · Results not recorded

NCT03463044 ↗PHASE1completed

CLASS-LEVEL SURROGATE (nangibotide): Phase I Ascending Single Intravenous Doses of MOTREM (LR12) in Healthy Male Subjects

Healthy Subjects

Enrolment: 27 · Results not recorded

NCT07176741 ↗Phase not recordednot yet recruiting

TARGET-LEVEL SURROGATE (observational): Hepatocyte TREM-1 Expression in Severe Symptomatic Alcohol-related Hepatitis

Severe Alcoholic Hepatitis

Enrolment: 300 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 26684249 ↗2015Reported benefit

TREM-1-accentuated lung injury via miR-155 is inhibited by LP17 nanomedicine.

MouseEndotoxin/LPSC57BL/6, including TREM-1 knockout animalsMale

Model: Lipopolysaccharide induced acute lung injury with neutrophilic inflammation, including lethal LPS dosing for survival studies

TREM-1 deletion or nanomicellar LP17 inhibition improved survival after lethal LPS and abolished neutrophilic lung inflammation through reduced miR-155 and restored SOCS-1.

Extraction: extract · Supplied extraction confidence: 0.55. Machine-extracted fields require source verification.

Loading the evidence…